Overview

Drug Use Investigation for REVOLADE (ITP)

Status:
Completed
Trial end date:
2020-10-16
Target enrollment:
Participant gender:
Summary
To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy. Thromboembolism
Details
Lead Sponsor:
Novartis
Novartis Pharmaceuticals